A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
A legfontosabb adatok
- Ki végzi
- SynAct Pharma Aps
- Hol
- Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 23 fő, tervezett
- Kezdés
- 2020. aug. 31.
- Tervezett befejezés
- 2026. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- 100 mg AP1189
- Placebo
- A regiszteradat frissítve
- 2026. március 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with idiopathic membranous nephropathy (iMN), a kidney disease, who lose a lot of protein in their urine. AP1189 or placebo is added to their usual ACE inhibitor or angiotensin II receptor blocker treatment.
- Életkor
- 18 to 85 years
- Nem
- Men and women. In Sweden, only women past menopause or surgically sterilized can join. In Denmark and Norway, women who could become pregnant must use reliable birth control and have negative pregnancy tests.
- A betegség stádiuma
- iMN diagnosed within 6 months before joining. Severe proteinuria: U-protein/creatinine ratio >3.0 g/g and/or U-albumin/creatinine ratio >2.0 g/g, and blood albumin below normal. Kidney function eGFR > 30 ml/min/1.73m2.
- Korábbi kezelés
- Treated with ACE inhibitors or angiotensin II receptor blockers for at least 1 months with stable blood pressure, or these drugs were stopped or not used because of low blood pressure or side effects. No systemic corticosteroids or other immune-suppressing drugs within 4 weeks before screening. No rituximab within 12 months.
- Biomarker vagy leletérték
- Anti-PLA2-Receptor positive, tested by a local lab within 6 months before joining.
A részvétel fő kizáró okai
- Another condition is the main cause of the protein loss
- Uncontrolled blood pressure above 160 mmHg systolic and/or 100 mmHg diastolic despite treatment
- Active cancer
- Pregnant or breastfeeding
- Major surgery within 8 weeks before screening, or surgery planned within 1 month after joining
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Written informed consent has been obtained prior to initiating any study-specific procedures
- Male and female subjects, 18 to 85 years of age diagnosed with iMN within 6 months prior to inclusion
- Diagnosed as anti-PLA2-Receptor positive by local laboratory within 6 months prior to inclusion
- Severe proteinuria defined by a U-protein/creatinine ratio >3.0 g/g and/or U-albumin/creatinine ratio >2.0 g/g and a P-albumin below the lower normal limit
- eGFR > 30 ml/min/1.73m2
- Treated with ACE- inhibitors or angiotensin II receptor blocker for a minimum of 1 months with a stable systemic arterial blood pressure OR treatment with ACE inhibitors and/or angiotensin receptor blocker was excluded or discontinued due to hypotension, intolerance or other side effect; Only Denmark and Norway:
- Females of child-bearing potential using reliable means of contraception or are post-menopausal
- Females of childbearing potential with negative pregnancy test at screening and baseline; Only Sweden:
- Post-menopausal women or women who are surgically sterilized
Ki nem vehet részt
- Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry
- Major surgery within 8 weeks prior to screening or planned surgery within 1 month following randomization
- Treated with systemic corticosteroids, or other immune suppressive, or immune modulating compounds within 4 weeks prior to screening and during the entire treatment period and until the final visit
- Treated with rituximab within 12 months of screening
- Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
- Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disease
- History of alcohol, drug, or chemical abuse within the 6 months prior to screening
- Clinicial findings that in the opinion of the investigator would suggest condition(s) other than iMN as a major cause of severe proteinuria
- Evidence of active malignant disease
- Any condition that in the view of the investigator would suggest that the patient is unable to comply with study protocol and procedures; Only Sweden:
- Blood pressure with systolic pressure above 160 mmHg and/or diastolic pressure above 100 mmHg despite antihypertensive treatment will in all cases be considered "uncontrolled"
- Pregnant women or nursing mothers
- Females of child-bearing potential
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 85 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.
A vizsgálat 2 csoportja
- 100 mg AP1189A vizsgált kezelés
100 mg AP1189. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
- PlaceboA vizsgált kezelés
Placebo. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Illeszkedési kérdések
- Forrás: NCT04456816: ki vehet részt
- A regiszteradat frissítve
- 2026. március 6.